Canaccord raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $81 from $80 and keeps a Buy rating on the shares. The firm said its 4Q report was incremental following the company’s preannouncement earlier this year, though encouraged by the company’s $75M raise via ATM that extends the runway into 2027.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals: Strong Buy Rating Backed by IMCIVREE’s Growth and Promising Pipeline Developments
- Rhythm Pharmaceuticals: Hold Rating Amid Strong Imcivree Sales and Upcoming HO Trial Data
- Rhythm Pharmaceuticals Reports Strong 2024 Growth and Strategic Advances
- Rhythm Pharmaceuticals: Strong Commercial Execution and Promising Pipeline Drive Buy Rating
- Positive Outlook for Rhythm Pharmaceuticals: Strong Q4 Revenue Growth and Promising Phase III Trial Catalysts